The Oxford Science Park

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Genomics England expands use of Oxford Nanopore sequencing in cancer

04 Apr 2022

Oxford Nanopore technology will be used by Genomics England to investigate and validate at increasing scale the benefits of sequencing for improving patient care and advancing research to develop new treatments. Genomics England’s “Long-Read Sequencing Programme” takes advantage of Oxford Nanopore’s ability to sequence any-length fragments of DNA, including long and ultra-long Oxford Nanopore has announced today the next steps in its... Read more

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon

21 Mar 2022

Spine consultant and clinical advisor Mr Nick Birch appointed as NED at OrthoSon Chairing the Clinical Advisory Group to guide clinical development strategy Oxford, UK, March 21 2022 – OrthoSon, which is developing minimally invasive and motion-restoring treatments for low back pain based on ultrasound and in-situ curing hydrogel implants, is pleased to announce the appointment of spine consultant Mr Nick Birch FRCS (Orth) to its Board... Read more

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA

16 Mar 2022

“Vatic COVID-19 Home Spike Test” OTC EUA Submitted to FDA Could Be Only Authorized SALIVA Rapid Test; Preferred to Nasal swabs by 4x in user testing OTC Self-Test Detects Virus Via ACE-2 Protein Binding to Trimeric Spike with Mouth Swab MARCH 16, 2022 – Vatic Health Limited (https://www.vatic.health/usa) today announces that it has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for... Read more

Exscientia & University of Oxford Launch “Xcellomics” Program

10 Mar 2022

Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery Program open at no-cost to any academic researcher interested in submitting a proposal OXFORD, England–(BUSINESS WIRE)– Exscientia (Nasdaq: EXAI) and the University of Oxford Target Discovery Institute (Oxford TDI) today announced the formation of Xcellomics – a... Read more

Mirobio Continues Expansion of Team With Key Appointments

08 Mar 2022

MIROBIO CONTINUES EXPANSION OF EXECUTIVE LEADERSHIP TEAM WITH KEY APPOINTMENTS TO ADVANCE DEVELOPMENT OF CHECKPOINT AGONIST ANTIBODIES FOR AUTOIMMUNE DISEASE Sanjay Keswani, MBBS, FRCP to join company as Chief Medical Officer bringing extensive experience in drug development and life sciences leadership Lynne Murray, Ph.D., MBA appointed as Chief Scientific Officer after leading MiroBio’s R&D efforts since October 2020 Enhanced leadership... Read more

News